Furthermore, the coexpression of activating KRAS mutations and inactivating BRAF mutations in mouse lung cells markedly enhanced tumor initiation, a phenomenon mediated by CRAF kinase activity [113,114], and effectively accelerated tumor progression to advanced lung adenocarcinomas. The gene discussed is KRAS; the disease is neoplasm.